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Abstract
Background: Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many
endemic countries; however, concerns have been raised over its potential under dosing in young children. We investigated
the influence of different dosing schedules on DP’s clinical efficacy.
Methods and Findings: A systematic search of the literature was conducted to identify all studies published between 1960
and February 2013, in which patients were enrolled and treated with DP. Principal investigators were approached and
invited to share individual patient data with the WorldWide Antimalarial Resistance Network (WWARN). Data were pooled
using a standardised methodology. Univariable and multivariable risk factors for parasite recrudescence were identified
using a Cox’s regression model with shared frailty across the study sites. Twenty-four published and two unpublished
studies (n= 7,072 patients) were included in the analysis. After correcting for reinfection by parasite genotyping, Kaplan–
Meier survival estimates were 97.7% (95% CI 97.3%–98.1%) at day 42 and 97.2% (95% CI 96.7%–97.7%) at day 63. Overall
28.6% (979/3,429) of children aged 1 to 5 years received a total dose of piperaquine below 48 mg/kg (the lower limit
recommended by WHO); this risk was 2.3–2.9-fold greater compared to that in the other age groups and was associated
with reduced efficacy at day 63 (94.4% [95% CI 92.6%–96.2%], p,0.001). After adjusting for confounding factors, the mg/kg
dose of piperaquine was found to be a significant predictor for recrudescence, the risk increasing by 13% (95% CI 5.0%–
21%) for every 5 mg/kg decrease in dose; p= 0.002. In a multivariable model increasing the target minimum total dose of
piperaquine in children aged 1 to 5 years old from 48 mg/kg to 59 mg/kg would halve the risk of treatment failure and cure
at least 95% of patients; such an increment was not associated with gastrointestinal toxicity in the ten studies in which this
could be assessed.
Conclusions: DP demonstrates excellent efficacy in a wide range of transmission settings; however, treatment failure is
associated with a lower dose of piperaquine, particularly in young children, suggesting potential for further dose
optimisation.
Please see later in the article for the Editors’ Summary.
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Introduction
Malaria is one of the leading causes of morbidity and mortality
in endemic countries. Children under the age of 5 years are
particularly vulnerable to failing treatment and developing
severe disease, usually attributed to their lower immunity and
premunition compared to older patients [1–3]. Prompt admin-
istration of highly effective antimalarial treatment can help to
ensure parasitological cure, decrease transmission, and reduce
the risk of complications and death; this approach is a key
component of current elimination efforts [4]. The current
consensus amongst policy makers advocates for artemisinin
combination therapy (ACT) to slow the emergence and spread of
antimalarial drug resistance [5]. This policy has been adopted in
over 80 malaria-endemic countries for patients with uncompli-
cated falciparum malaria [6]. The high potency of the artemisinin
component results in a rapid initial reduction in parasite
biomass, with the sustained activity of the more slowly
eliminated partner drug preventing subsequent recrudescent
infections. Highly effective antimalarial treatment requires the
administration of an optimised treatment regimen tailored to the
weight and age of the patient. Sub-optimal dosing of either
component can result in incomplete elimination of the parasite
biomass and subsequent recrudescence, both of which are
important driving forces for the selection of parasites with
reduced drug susceptibility [7,8].
The combination of dihydroartemisinin-piperaquine (DP) has
been assessed in clinical trials for almost a decade, and shown to be
highly efficacious against both Plasmodium falciparum and P. vivax
infections [3,9,10]. Since 2010, DP has been recommended by
WHO for the treatment of uncomplicated falciparum malaria [5],
providing a promising alternative to other currently available
ACTs, based upon its high efficacy, excellent safety profile, once
daily dosing scheme, and prolonged post-treatment prophylactic
protection [11–13]. The target doses of both dihydroartemisinin
(DHA) and piperaquine (PIP) are usually quoted as the total mg/
kg dose taken during the 3-day regimen. As is often the case, these
recommendations were developed empirically in the early stages of
the drug development with additional evidence provided by
subsequent sparse pharmacokinetic data [14,15]. In clinical
practice, dosing strategies are usually pragmatic and based upon
set weight or age banding. The inevitable consequence is that
patients at the margins of these bands receive either lower or
higher weight adjusted dosages. Furthermore, paediatric doses are
often extrapolated from adult doses, since detailed pharmacoki-
netic data in children are frequently unavailable [15]. Thus, as
detailed studies of a newly introduced drug are conducted, re-
assessment of the original dosing recommendations based on a
Figure 1. Patient flowchart.
doi:10.1371/journal.pmed.1001564.g001
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much larger body of evidence are needed to ensure that the
original target doses are optimal for the key target populations,
most notably the young children who carry the highest burden of
disease in high intensity malaria transmission areas.
The Worldwide Antimalarial Resistance Network (WWARN)
brings together malaria researchers from across the world. This
collaborative resource provides a unique opportunity to conduct a
series of individual patient data meta-analyses in which the dosing
strategies of the recommended ACTs can be reviewed, to define
the spectrum of treatment doses actually administered, and the
degree to which these dose variations impact on the therapeutic
efficacy [16]. The size of these pooled analyses provides
unprecedented power and novel insights into the determinants
of antimalarial efficacy. The first of these studies is focussed on the
combination DP to explore the relationship between weight
adjusted drug dosage (mg/kg) and therapeutic efficacy.
Methods
Data Pooling
All published antimalarial clinical trials reported in PubMed
were identified through a systematic search of the literature of
publications between 1st January 1960 and 15th February 2013. A
further search was then made for those studies enrolling patients
and treating them with DP. Further information on these literature
reviews are available on the WWARN website [16]. Specific
details on the relevant DP studies are presented in Texts S1 and S2
[11–13,17–37]. Since the literature review was conducted, a
further three clinical studies enrolling 408 patients treated with DP
have been published. All research groups who have contributed to
the WWARN data repository were also asked whether they were
aware of any unpublished or ongoing clinical trials involving DP.
Individual study protocols were available for all trials, either from
the publication or as a metafile submitted with the raw data. The
principal investigators of relevant studies were invited to contrib-
ute individual patient data to WWARN for a collaborative meta-
analysis. A study was deemed eligible for the meta-analysis if
patients were recruited and treated with DP and evaluated
prospectively for clinical efficacy against P. falciparum (either alone
or mixed infections), for a minimum of 28 days. Studies were
included only if information was available on the treatment dose
administered, the age and weight of the patient, and if genotyping
was performed to distinguish between new infections and
recrudescent infections. Both randomized and non-randomized
studies were included. Data were anonymised, uploaded to the
WWARN repository, and standardised using a methodology
Table 1. Studies included in the meta-analysis.
Study Year Region Country
Number of Patients
Treated With DP
Age Range (y Except
Where Indicated) Reference
4ABC Study Group 2011 Africa Multicentred 1,475 0.5–5 [12]
Adam et al. 2010 Africa Sudan 75 $0.5 [17]
Arinaitwe et al. 2009 Africa Uganda 119 1 m to 1 [18]
Ashley et al. 2004 Asia Thailand 487 1–65 [19]
Ashley et al. 2005 Asia Thailand 333 1–65 [20]
Awab et al. 2010 Asia Afghanistan 59 2–52 Unpublished
Bassat et al. 2009 Africa Multicentred 1,038 0.5–5 [11]
Borrmann et al. 2011 Africa Kenya 233 0.5–5 [21]
Gaye et al. 2011 Africa Senegal 124 6–63 Unpublished
Grande et al. 2007 S. America Peru 262 5–60 [22]
Hasugian et al. 2007 Asia Indonesia 168 1–56 [23]
Janssens et al. 2007 Asia Cambodia 228 2–65 [24]
Kamya et al. 2007 Africa Uganda 211 0.5–10 [25]
Karema et al. 2006 Africa Rwanda 252 1–5 [26]
Karunajeewa et al. 2008 Asia Papua New Guinea 186 0.5–5 [27]
Mayxay et al. 2006 Asia Laos 110 $1 [28]
Mens et al. 2008 Africa Kenya 73 0.5–12 [29]
Ratcliff et al. 2007 Asia Indonesia 387 1–60 [30]
Sawa et al. 2013 Africa Kenya 145 0.5–10 [31]
Smithuis et al. 2006 Asia Myanmar 327 $1 [32]
Smithuis et al. 2010 Asia Myanmar 161 $1 [33]
Tran et al. 2012 Asia Vietnam 55 .10 [34]
Valecha et al. 2010 Asia Multicentred 769 3 m–65 [13]
Yavo et al. 2011 Africa Multicentred 197 2–77 [35]
Yeka et al. 2008 Africa Uganda 215 0.5–10 [36]
Zongo et al. 2007 Africa Burkina Faso 187 $0.5 [37]
Full details of the references and study design are available in Text S1.
doi:10.1371/journal.pmed.1001564.t001
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described in the WWARN Data Management and Statistical
Analysis Plan (Text S3) [38].
Ethical Approval
All data included in this analysis were obtained in accordance
with the laws and ethical approvals applicable to the countries in
which the studies were conducted, and were obtained with the
knowledge and consent of the individual to which they relate. Data
were fully anonymised either before or during the process of
uploading to the WWARN repository. Ethical approval to conduct
individual participant data pooled analyses was granted to
WWARN by the Oxford Tropical Research Ethics Committee
(OxTREC).
Dosing Calculation
Where possible, the dose of DHA and PIP administered was
calculated from the individual number of tablets administered to
each patient daily. Where such data were not available, back-
calculations were made, based on the dosing strategy presented in
the study protocol, assuming correct adherence to the protocol.
Only patients completing a full 3-day treatment regimen and
included in the original analysis, were included in the meta-analysis.
Table 2. Baseline characteristics of patients included in the analysis.
Variable Asia Africa South Americaa Overall
n 2,807 (39.7%) 4,009 (56.7%) 256 (3.6%) 7,072 (100%)
Study period 2002–2011 2003–2010 2003–2005 2002–2011
Gender
Female 34.0% [953/2,807] 46.8% [1,875/4,009] 42.2% [108/256] 41.5% [2,936/7,072]
Male 66.1% [1,854/2,807] 50.3% [2,018/4,009] 57.8% [148/256] 56.8% [4,020/7,072]
Missing 0% [0/2,807] 2.9% [116/4,009] 0% [0/256] 1.6% [116/7,072]
Age
Median age [range] in years 18 [0.7–65] 2.6 [0.35–75] 23.5 [5–59] 4.2 [0.35–75]
,1 y 0.2% [5/2,807] 10.8% [434/4,009] 0% [0/256] 6.2% [439/7,072]
1 to ,5 y 12.9% [361/2,807] 76.5% [3,068/4,009] 0% [0/256] 48.5% [3,429/7,072]
5 to ,12 y 20.9% [587/2,807] 7.8% [312/4,009] 17.6% [45/256] 13.4% [944/7,072]
$12 y 66.1% [1,854/2,807] 4.9% [195/4,009] 82.4% [211/256] 31.9% [2,260/7,072]
Body weight
Median weight [range] in kg 43 [5–87] 11.6 [2,5–98] 52.5 [1,14–93.5] 14.9 [5–98]
5 to ,7 kg 0.2% [6/2,807] 2.8% [111/4,009] 0% [0/256] 1.7% [117/7,072]
7 to ,13 kg 11.0% [309/2,807] 58.4% [2,342/4,009] 0% [0/256] 37.5% [2,651/7,072]
13 to ,24 kg 19.2% [540/2,807] 31.6% [1,265/4,009] 12.5% [32/256] 26.0% [1,837/7,072]
24 to ,36 kg 9.8% [276/2,807] 2.8% [112/4,009] 9.4% [24/256] 5.8% [412/7,072]
36 to ,75 kg 59.4% [1,666/2,807] 4.1% [165/4,009] 76.6% [196/256] 28.7% [2027/7,072]
75 to ,100 kg 0.4% [10/2,807] 0.3% [14/4,009] 1.6% [4/256] 0.4% [28/7,072]
Treatment supervision
Full 88.7% [2,490/2,807] 93.0% [3,728/4,009] 100% [256/256] 91.5% [6,474/7,072]
Partial 11.3% [317/2,807] 3.9% [157/4,009] 0% [0/256] 6.7% [474/7,072]
Not stated 0% [0/2,807] 3.1% [124/4,009] 0% [0/256] 1.8% [124/7,072]
Drug formulationsb
Eurartesim 27.0% [759/2,807] 65.4% [2,622/4,009] 0% [0/256] 47.8% [3,381/7,072]
Artekin 59.3% [1,664/2,807] 6.2% [249/4,009] 100% [256/256] 30.7% [2,169/7,072]
Duo-Cotecxin 11.7% [329/2,807] 28.4% [1,138/4,009] 0% [0/256] 20.7% [1,467/7,072]
Artecan 2.0% [55/2,807] 0% [0/4,009] 0% [0/256] 0.8% [55/7,072]
Enrolment clinical parameters
Median parasitemia [IQR] 8,530 [2,240.5–29,026.8] 26,520 [8,739–62,400] 6,274.5 [3,272–9,995] 16,580 [4,782–473,000]
Mixed infections with P. vivax 3.4% [95/2,807] 0% [0/4,009] 0% [0/256] 1.3% [95/7,072]
Haemoglobin [mean 6 SD] 11.262.6 9.461.8 12.261.7 10.262.3
Anemic (Hb ,10 g/dl) 29.9% [765/2,558] 61.8% [2,247/3,639] 7.4% [19/256] 47.0% [3,031/6,453]
Gametocyte carriage 19.1% [291/1,527] 9.7% [361/3,713] 12.5% [32/256] 12.5% [684/5,496]
Fever (.37.5uC) 49.2% [1,197/2,433] 61.5% [2,421/3,938] 46.1% [118/256] 56.4% [3,736/6,627]
aData from one study conducted in Peru.
bDHA-PIP tablets strength was 40 mg DHA + 320 mg PIP or 20 mg DHA + 160 mg PIP in paediatric formulation (full details are given in Text S1).
doi:10.1371/journal.pmed.1001564.t002
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Classification of Study Sites in Transmission Intensity
Zones
Study sites were categorised into three strata according to known
epidemiology: low, moderate, and high transmission settings. The
classification of transmission intensity was based on the author’s
classification of the site as reported in the study publication. Where
no transmission information was reported, then the transmission
intensity was defined based on the triangulation of information
available from: (i) the study protocol(s), (ii) observed reinfection rate,
and (iii) transmission estimates obtained from the Malaria Atlas
Project [39]. Further information about this classification is
available in the Text S4.
Statistical Analysis
All statistical analyses were carried out using R (Version 2.14.0,
The R Foundation for Statistical Computing), on the basis of an a
priori statistical plan [40]. The full statistical plan is available in
Text S5. The primary endpoint used in this analysis was the PCR-
adjusted risk of P. falciparum recrudescence at the end of study
follow-up. Secondary endpoints included the new infections of P.
falciparum, parasitological clearance rates, and gametocyte carriage.
The incidence risk of these endpoints at day 28, day 42, and day
63 was computed using survival analysis (Kaplan–Meier [K-M]
estimates). Definitions of outcome status and censoring are
detailed in the WWARN Clinical Module DMSAP v1.2 [38].
The K-M estimates were generated using all the individual patient
data and any comparison of K-M survival curves were performed
using log rank tests stratified by study and study site. For risk factor
analyses, the dose of PIP was considered as a risk factor for
recrudescence and reinfection because of its long half-life, whereas
the dose of DHA was considered as a risk factor for parasitological
clearance rates and gametocyte carriage due to its more rapid
anti-parasitic activity and its shorter half-life. Univariable and
multivariable analysis of risk factors associated with the primary
and secondary endpoints (PCR-adjusted new infection) of interest
was conducted using Cox’s proportional hazards regression model
in a one-step analysis by combining all the individual patient data
in a single analysis. In order to account for within study clustering,
a shared frailty model was used, in which a random effect was
applied to both the study and study site (by combining study and
study sites). The overall assumption of proportional hazards was
assessed by a global test, and also separately for each of the
covariates in the final model. The assumption of proportional
hazards was tested for each of the individual studies, although this
could not be applied to studies with a low number of events (fewer
than ten). All variables significant at 10% level in univariable
analysis were included in the multivariable analysis. Inclusion of
covariates in the final model was based on their effect on model
coefficients and the degree to which they improved the overall
model based on a likelihood ratio test. The manufacturer of the
drugs used in the studies and the methodology of calculation of mg
per kg dose were included as potential covariates.
The population attributable risks (PARs) for treatment failure
were calculated based on the prevalence of the risk factor in the
population and its associated relative risk (adjusted hazard ratio)
[41]. PARs were computed for exposure to a PIP dose below
48 mg/kg (the lower bound of WHO defined therapeutic range for
PIP) and for a baseline parasitemia greater than 100,000/ml. The
overall PAR (for a combination of risk factors), which is non-
additive, was calculated as 12[(12PAR )16(12PAR )26…6(12
PARn)]. In the final multivariable model, the predicted effect of
increasing the mg/kg dose of PIP was calculated for every five unit
increase, starting from 30 mg/kg. The 95th percentile of predicted
risk was computed for each mg/kg dosage of PIP using each patient
individual covariates evaluated at average random effect. Although
Table 3. Total piperaquine and dihydroartemisinin dose by age and weight categories.
Characteristics n PIP Dosage (mg/kg) DHA Dosage (mg/kg) Exposure to Dose Outside WHO Range
Median [IQR] Range Median [IQR] Range
PIP Dose
,48 mg/kg
PIP Dose
.78 mg/kg DHA ,6 mg/kga
Overall 7,072 53.3 [48–62.6] 18.2–182.9 6.8 [6.0–8.0] 2.3–22.9 20.3% [1,437/7,072] 2.2% [155/7,072] 19.6% [1,387/7,072]
Age category
,1 y 439 60 [53.3–67.61] 34.8–80.0 7.5 [6.7–8.5] 4.4–10.0 12.5% [55/439] 5.7% [25/439] 12.5% [55/439]
1 to ,5 y 3,429 53.3 [45.7–64.0] 22.5–96.0 6.7 [5.7–8.0] 2.8–13.9 28.6% [979/3,429] 0.6% [20/3,429] 28.5% [976/3,429]
5 to ,12 y 944 57.1 [51.2–65.4] 25.3–182.9 7.2 [6.4–8.4] 3.2–22.9 9.5% [90/944] 8.3% [78/944] 8.3% [78/944]
$12 y 2,260 53.3 [49.7–58.2] 18.2–151.6 6.7 [6.3–7.5] 2.3–18.9 13.9% [313/2,260] 1.4% [32/2,260] 12.3% [278/2,260]
Weight category
5 to ,7 kg 117 42.9 [37.5–77.4] 34.8–80 5.4 [4.7–9.7] 4.4–10 53.9% [63/117] 23.9% [28/117] 53.9% [63/117]
7 to ,13 kg 2,651 48.4 [43.6–58.5] 22.5–182.9 6.1 [5.5–7.4] 2.8–22.9 36.2% [960/2,651] 1.1% [30/2,651] 36.2% [960/2,651]
13 to ,24 kg 1,837 64.0 [55.4–68.6] 25.3–151.6 8.0 [6.9–8.6] 3.2–18.9 5.1% [94/1,837] 3.5% [64/1,837] 4.4% [80/1,837]
24 to ,36 kg 412 57.7 [53.3–66.2] 38.8–98.5 7.3 [6.8–8.6] 4.9–13.9 2.4% [10/412] 5.3% [22/412] 2.4% [10/412]
36 to ,75 kg 2,027 53.3 [49.2–57.6] 18.2–80.0 6.7 [6.2–7.4] 2.3–13.3 14.3% [290/2,027] 0.5% [11/2,027] 12.5% [254/2,027]
75 to ,100 kg 28 37.4 [32.8–48.3] 26.1–56.5 4.7 [4.1–6.04] 3.3–7.1 71.4% [20/28] 0% [0/28] 71.4% [20/28]
Region
Asia 2,807 55.4 [50.5–62.6] 18.2–182.9 7.1 [6.4–8.0] 2.2–22.9 11.4% [320/2,807] 3.7% [104/2,807] 9.6% [270/2,807]
Africa 4,009 53.3 [46.2–64.0] 25.3–96.0 6.7 [5.8–8.0] 3.2–12 27.5% [1,103/4,009] 1.3% [51/4,009] 27.51% [1,103/4,009]
S. America 256 52.1 [50.1–54.9] 46.6–68.6 6.5 [6.3–6.9] 5.8–8.57 5.5% [14/256] 0% [0/256] 5.5% [14/256]
aThe WHO therapeutic guidelines recommend a target dose for PIP of 54 mg/kg over 3 days with a range from 48 to 78 mg/kg; and a target dose for DHA of 12 mg/kg
over 3 days with a range from 6 to 30 mg/kg [5]. No patient was exposed to a DHA dose .30 mg/kg.
doi:10.1371/journal.pmed.1001564.t003
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the primary analysis was focussed on risk factors affecting the
efficacy of the DP, the relationship between drug dose and
gastrointestinal side effects (vomiting and diarrhoea) was also
explored using logistic regression with random effects fitted for the
individual study and study sites.
Results
Characteristics of Included Studies
In total, 23 principal investigators (PIs) were approached, of
whom 16 submitted data from 29 studies contributing 8,081
patients for the pooled analysis. These data were derived from
77.7% (7,898/10,168) of patients reported in 77.1% (27/35) of the
targeted published studies and an additional 183 patients from two
unpublished studies (Figure 1). Three of these studies (n=375) did
not meet the inclusion criteria and 634 (8.2%) patients from the rest
of the studies were excluded for protocol violations. In total 7,072
patients from 26 studies representing 70% of the targeted published
literature on this treatment regimen, were included in the final
analysis (Figure 1), of whom 2,807 (39.7%) were from 12 studies
conducted in Asia, 4,009 (56.7%) from 13 studies from Africa, and
256 (3.6%) from one study conducted in South America (Table 1).
Dosing was based on age and weight categories in two studies
(n=471), age category in one study (n=124), and on weight bands
in the remaining 23 studies (n=6,477). Six studies (n=2,072)
followed up patients for 28 days, 12 studies (n=2,664) for 42 days,
one study (n=58) for 56 days, and seven studies (n=2,278) for 63 or
more days. Three different combinations of DHA and PIP were
used in the different studies; 51.4% (n=3,636) of patients were
treated with Artekin or Duo-Cotecxin(Holley-Cotec Pharmaceuti-
cals Co), 47.8% (n=3,381) with Eurartesim (Sigma Tau Industrie
Farmaceutiche Riunite), and 0.8% (n=55) of the patients were
treated with Artecan (OPC Pharmaceutical). Drug intake was
reported in all studies, with full supervision in 24 (92.3%) of the
studies, partial supervision in one (3.8%), and a combination of full
supervision and no supervision in one study (3.8%). Overall 2,628
(37.2%) patients were recruited in areas of high malaria transmis-
sion, 1,194 (16.9%) in areas of moderate transmission, and 3,250
(46%) in low transmission areas. Parasite genotyping was carried out
in 25 studies: with 17 studies (n=5,751) using three markers (MSP1,
MSP2, and GLURP); three studies (n=528) using two markers
(MSP1, MSP2); three studies (n=578) using MSP1, MSP2, and
microsatellites; one study (n=116) using only microsatellites; and in
one study, the genotyping method was not stated (n=41).
Genotyping was not carried out in one study (n=58) as there were
no recurrent infections.
Baseline Characteristics
The baseline characteristics of patients included in the analysis
are documented in Table 2. The median age of patients was 4.2
years (range 0.35–75 years), with 6.2% (439/7,072) younger than
1 year, 48.5% (3,429/7,072) from 1 up to 5 years, 13.4% (944/
7,072) from 5 up to 12 years, and 31.9% (2,260/7,072) being 12
years or older. Compared to patients from Asia, those from
African sites were significantly younger (median: 2.6 years
[interquartile range (IQR): 1.5–4, range: 0.35–75] versus median:
18 years [IQR: 8–30, range: 0.7–65], respectively; p,0.001) and
had a higher median baseline parasitemia (26,520 ml21 [IQR:
8,379–62,400] versus 8,530 ml21 [IQR: 2,240–29,026]; p,0.001).
In the 256 patients from South America the median age was 23.5
years (IQR: 13–39) with a median baseline parasitemia of
6,274.5 ml21 (IQR: 3,272–9,995).
Distribution of Dihydroartemisinin Dosing
The median total dose of DHA administered was 6.8 mg/kg
[IQR: 6–8, range: 2.3–22.9] (Table 3). Overall 19.6% (1,387/
Figure 2. Available patient data within each age category for (A) dihydroartemisinin and (B) piperaquine. The patients receiving a total
mg/kg dose below the WHO therapeutic range (6 mg/kg and 48 mg/kg, respectively) are shown in dark columns and as a percentage of all patients
on top of the bar.
doi:10.1371/journal.pmed.1001564.g002
WWARN DHA-Piperaquine Dose Impact Study
PLOS Medicine | www.plosmedicine.org 6 December 2013 | Volume 10 | Issue 12 | e1001564
7,072) of the patients received a total dose of DHA less than 6 mg/
kg (the lower limit for DHA recommended by the WHO),
although this varied significantly between age groups. None of the
patients were exposed to a total DHA dose greater than 30 mg/kg
(the upper limit recommended by the WHO). In a multivariable
analysis controlling for weight, children from 1 up to 5 years were
at the greatest risk of being exposed to a total dose of DHA ,
6 mg/kg compared to infants younger than 1 year (adjusted odds
ratio [AOR]=1.7 [95% CI 1.2–2.3; p=0.002]), children from 5
up to 12 years (AOR=6.6 [95% CI 4.4–4.9; p,0.001]) and 12
years or older (AOR=72.9 [95% CI 37.3–142.5; p,0.001]);
p,0.005 for all comparisons. Patients from African sites were at
greater risk of being exposed to a total dose of DHA dose below
6 mg/kg, compared to those from Asia (odds ratio [OR]= 3.3
[95% CI 1.5–7.6; p=0.004]), but, this was no longer significant
after adjusting for the age and weight of the patient (AOR=2.13
[95% CI 0.90–5.07; p=0.09]).
Distribution of Piperaquine Dosing
The median total dose of PIP administered was 53.3 mg/kg
(IQR: 48.0–62.6, range: 18.2–182.9 mg/kg), but this varied
significantly between age groups (Table 3). Overall, 20.3%
(1,437/7,072) of patients received a total dose of PIP below
48 mg/kg (the lower limit recommended by WHO) (Figure 2),
whereas only 2.2% (155/7,072) received a dose greater than
78 mg/kg (the WHO upper limit). Young children (from 1 up to 5
years of age) were at greater risk of receiving a total dose of PIP
below 48 mg/kg compared to infants ,1 year (OR=2.3 [95% CI
1.7–3.2; p,0.001]), children from 5 up to 12 years (OR=2.9 [95%
CI 2.0–4.2; p,0.001]), and patients 12 years or older (OR=2.3
[95% CI 1.7–3.3; p,0.001]). These comparisons remained
statistically significant after adjusting for body weight (p,0.005 for
all comparisons). Patients from African sites were at greater risk of
being exposed to a total dose of PIP below 48 mg/kg, compared to
those from Asia (OR=3.0 [95%CI 1.3–7.0; p=0.01]), however like
DHA, this was no longer significant after adjusting for age. There
was no significant difference in the risk of under dosing PIP between
patients from South America and Asia.
Early Parasitological Response
The overall speed of parasite clearance was rapid (Table 4), with
the overall parasite positivity rate (PPR) decreasing from 59%
(3,083/5,222) on day 1, to 9.1% (576/6,321) on day 2, and 1.2%
(70/5,697) on day 3. The PPR on day 1 and day 2 was higher in
children younger than 5 years compared to older children and
adults ($5 years), with this difference being greatest on day 1
(OR=1.70 [95% CI 120–2.40; p=0.002]).
The dose of DP was a significant predictor of parasite positivity
on day 3, with an OR of 0.81 (95% CI 0.67–0.97, p=0.022) per
unit increase in mg/kg of DHA and 0.97 (95% CI 0.94–0.99;
p=0.026) per unit increase in mg/kg PIP dose. These ORs
remained statistically significant after controlling for age, baseline
parasitemia, and transmission setting, AOR=0.80 (95% CI 0.66–
0.96; p=0.017) and 0.97 (95% CI 0.94–0.99; p=0.020) per unit
increase in mg/kg DHA and PIP, respectively. The dose of DP
was not a significant predictor of parasite positivity on day 1 or day
2.
Late Parasitological Response
In total, 704 (9.9%) patients had recurrent parasitemia detected
during follow-up, of whom 136 (1.9%, 136/7,072) were confirmed
by PCR as true recrudescence. In seven studies with a follow-up
duration of 63 days (n=2,278 and 34 confirmed recrudescent
failures), nine (26.5%) patients failed before day 28, 16 (47%)
patients failed between day 28 and day 42, and nine (26.5%)
patients recurred after day 42. Overall PCR-corrected K-M
survival estimates were 98.8% (95% CI 98.5–99%) at day 28,
97.7% (95% CI 97.3–98.1%) at day 42, and 97.2% (95% CI 96.7–
97.7%) at day 63 (Figure 3; Table 5). The corresponding figures in
children from 1 up to 5 years of age were 97.9% (95% CI 97.4–
98.4%) at day 28, 95.8% (95% CI 94.9–96.7%) at day 42, and
94.4% (95% CI 92.6–96.2%) at day 63.
Table 4. Parasite positivity rates on days 1, 2, and 3.
Characteristics All Patients Day 1 Day 2 Day 3
Age category n Positive PPR [95% CI]a Positive PPR [95%CI]a Positive PPR [95% CI]a
,1 y 439 144/226 63.7 [48.8–78.6] 27/433 6.2 [2–10.5] 3/432 0.7 [0–1.5]
1 to ,5 y 3,429 1,610/2,522 63.8 [54.1–73.6] 283/3,153 9 [3.1–14.8] 26/3,061 0.8 [0–1.7]
5 to ,12 y 944 303/541 56 [40.7–71.4] 39/713 5.5 [1.1–9.8] 8/559 1.4 [0–2.9]
$12 y 2,260 1,026/1,933 53.1 [42.5–63.6] 227/2,022 11.2 [4.3–18.2] 33/1,645 2 [0.5–3.5]
DHA dose (mg/kg)
,6 mg/kg 1,387 718/1,137 63.1 [53.6–72.7] 140/1,297 10.8 [4.7–16.8] 18/1,212 1.5 [0.5–2.5]
$6 mg/kg 5,685 2,365/4,085 57.9 [50–65.8] 436/5,024 8.7 [4.7–12.7] 52/4,485 1.2 [0.4–1.9]
PQP dose (mg/kg)
,48 mg/kg 1,437 750/1,185 63.3 [54.1–72.4] 144/1,345 10.7 [4.9–16.5] 19/1,257 1.5 [0.5–2.5]
$48 mg/kg 5,635 2,333/4,037 57.8 [49.8–65.8] 432/4,976 8.7 [4.6–12.7] 51/4,440 1.1 [0.4–1.9]
Region
Asia 2,807 1,316/2,238 58.8 [47.5–70.1] 266/2,160 12.3 [5.7–18.9] 40/1,546 2.6 [1.2–4]
Africa 4,009 1,685/2,730 61.7 [51.5–72] 307/3,907 7.9 [2.6–13.1] 30/3,897 0.8 [0–1.5]
S. America 256 3/254 32.3 [26.8–38.3] 3/254 1.2 [0.4–3.4] 0/354 0 [0–1.5]
Overall 7,072 3,083/5,222 59 [51.3–66.8] 576/6,321 9.1 [5–13.3] 70/5,697 1.2 [0.5–2]
aParasite positivity rates were calculated from those with in who a blood film was taken on that day; cases without a smear were removed from the denominator.
doi:10.1371/journal.pmed.1001564.t004
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Risk Factors for Recrudescence
Six univariate factors on admission were associated with
recrudescent parasitemia by day 42: the mg/kg PIP dose (hazard
ratio [HR]=0.86 [95% CI 0.78–0.94; p=0.001] for every 5 mg/
kg increase), baseline parasitemia (log scale) (HR=1.26 [95% CI
1.10–1.44; p=0.001]), presence of gametocytes at baseline
(HR=1.79 [95% CI 1.05–3.04; p=0.032]), being from 1 up to
5 years of age (HR=3.71 [95% CI 1.66–8.26; p=0.002]),
admission haemoglobin (HR=0.92 [95% CI:0.83–1.01;
p=0.080]), and body weight (HR=0.97 [95% CI 0.95–0.99;
p=0.010]) (Table 6). In a multivariable model, after adjusting for
age and parasitemia the dose of PIP was a significant predictor for
recrudescence (adjusted hazard ratio [AHR]= 0.87 [95% CI
0.79–0.95; p=0.002] for every 5 mg/kg increase in PIP dose). In
total 3% (44/1,437) of patients exposed to a dose of PIP less than
48 mg/kg experienced a recrudescent infection compared to 1.5%
(83/5,633) of those who received a dose greater than 48 mg/kg kg
(HR=1.48 [95% CI 0.99–2.19; p=0.05]).
Overall, the risk of recrudescence was greatest in the 1 up to 5
year age group, rising to 5.6% (95% CI 3.8–7.4) by day 63
(Tables 5 and 6). Compared to patients older than 12 years,
children from 1 up to 5 years of age had HR of 3.71 (95% CI
1.66–8.26; p=0.002) for the risk of recrudescence. The risk
remained significant after adjusting for baseline parasitemia, and
the mg/kg dose of PIP (AHR=3.22 [95% CI 1.42–7.33;
p=0.005]). The population attributable risks of recrudescence
are presented in Table 6. Overall, the model accounted for 65.1%
of all treatment failures, with a low dose of PIP accounting for
7.7% and children from 1 up to 5 years of age for 53.5%.
In children aged from 1 up to 5 years of age (n=3,429, 98
recrudescent failures), five risk factors on admission were associated
with recrudescence failure by day 42; age (years) (HR=0.73 [95%
CI 0.59–0.89; p=0.002]), body weight (HR=0.87 [95% CI 0.79–
0.96; p=0.006]), enrolment parasitemia (log-scale) (HR= 1.22
[95% CI 1.04–1.43; p=0.015]), admission haemoglobin
(HR=0.90 [95% CI 0.80–1.01; p=0.079]), and mg/kg PIP
dose (HR= 0.86 [95% CI 0.77–0.95; p=0.003] for every 5 unit
mg/kg). Since weight and age were collinear only weight was
included in the multivariable analysis. In the multivariable model,
the dose of PIP remained a significant risk factor (AHR=0.87
[95% CI 0.78–0.97, p=0.013] for every 5 unit mg/kg). The
median total dose of PIP was 48.0 mg/kg (IQR: 42.8–53.3 mg/
kg) in young children with recrudescence compared to 53.3 mg/
kg (IQR: 45.7–64.0 mg/kg) in those who were cured (p,0.001).
Figure 3. PCR adjusted risk of recrudescent and new infections at day 42 for individual studies. The full citations for these studies are
available in Text S1. The figure excludes data from 6 studies in which active follow-up was stopped at Day 28 [12,17,18,26,29,36]. The results for
Ashley-2004 [19] and Ashley-2005 [20] are presented pooled since the datasets did not distinguish between the studies.
doi:10.1371/journal.pmed.1001564.g003
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In the multivariable model every 5 unit increase in mg/kg dose of
PIP was associated with a 13% (95% CI 3–22%) decrease in risk
of recrudesecence; p=0.013. In a predicted risk model, generated
from patients’ individual covariates, a dose of 59 mg/kg PIP was
sufficient to ensure a day 42 cure rate above 95% (Figure 4).
Children aged from 1 up to 5 years receiving a PIP dose below
59 mg/kg were at twice the risk of recrudescence (AHR=2.03
[95% CI 1.2–3.42; p=0.008]), and this accounted for 39.3%
(PAR) of all recrudescent infections. By day 42 the risk of
recrudescence in patients receiving a PIP dose below this
threshold was 5.5% (95% CI 4.2–6.7) compared to 2.1% (95%:
1.1–3.0) in patients receiving a higher dose, p,0.001 (Figure 5).
Gametocyte Carriage
The overall gametocyte carriage decreased from 12.3% at
enrolment to 8.3% on day 7 a reduction of 4.0% (95% CI 2.8%–
5.2%) and fell further thereafter; p,0.001 (Figure 6). Exposure to
a total DHA dose below 6 mg/kg was associated with a non-
significant increased risk of gametocyte carriage on day 7
(OR=1.34 [95% CI 0.97–1.85; p=0.076]); however, this was
significant after adjusting for age, baseline gametocytemia, and
parasitemia (AOR=1.56 [95% CI 1.08–2.24; p=0.015]). The
dose of DHA did not correlate with the risk of gametocyte
reappearing.
Safety Parameters
In total 3.2% (54/1,669) of patients with full documentation of
tablet administration did not complete a full course of DP. In four
(7.4%) cases this was due to adverse events (two patients had
recurrent vomiting, one had diarrhoea, and one patient developed
a rash). Information regarding acute vomiting of medication was
available for ten studies with 8.8% (376/4,272) of the patients
vomiting within an hour of drug administration, this proportion
being greatest in infants and children from 1 up to 5 years of age
(Table 7). Data on patients vomiting within the preceding
24 hours were available in 13 studies and reported in 16.6%
(736/4,440) of the patients. The incidence of diarrhoea within the
first 7 days of follow-up was available in 11 studies, and occurred
in 11.6% (530/4,560) of patients. After controlling for age,
parasitemia, and fever at presentation the risks of vomiting or
diarrhoea were not correlated with the mg/kg dose of PIP.
A total of 21 severe adverse events (SAEs) were reported from
five studies (n=2,873), but in none of the patients in eight other
studies (n=1,120). In the remaining 13 studies, severe adverse
events were not reported or the data were unavailable. These
severe events included one patient with diarrheal disease,
considered unrelated to treatment who died, three patients with
severe anaemia, three with recurrent vomiting, two with pyomyo-
sitis, two with acute pyelonephritis, two with recurrent P. falciparum
infections, and one patient each with one of the following:
abnormal skin, a swollen arm, anorexia, aspiration pneumonia,
cerebritis, convulsions, high fever, and hyperparasitemia P.
falciparum infection. Five patients were younger than 1 year, five
were from 1 up to 5 years of age, and eleven were older than 5
years. There was no evidence of these SAEs being related with the
mg/kg dose of PIP.
Discussion
Over the last decade, a number of clinical trials have
highlighted the impressive antimalarial efficacy of DP, which
was added to the WHO list of antimalarials recommended for first
line therapy in 2010 [5]. We present the largest pooled analysis of
DP efficacy yet described, to our knowledge, including more than
two-thirds of all data from the published literature. Overall the
efficacy of DP was excellent, exceeding 98% at day 28 and 97% at
day 42, consistent with published results from Africa
[12,17,18,21,25,26,29,31,35–37], Asia [13,19,20,23,24,27,28,
30,32–34], and South America [22]. However our study reveals
an important sub-group of patients who are at particular risk of
treatment failure.
ACTs have become a cornerstone of the current global strategy
for the control and elimination of malaria and are considered a
major factor in achieving the substantial gains in malaria control
observed in many endemic settings over the past decade.
However, these gains are now under threat from the emergence
of antimalarial drug resistance, both to the artemisinin derivatives
[42,43] and their partner drugs [44]. It is crucial that current
treatment guidelines advocate that drug regimens be deployed
using optimal dosing strategies to maximise the likelihood of rapid
clinical and parasitological cure, minimize transmission, and
retard the onset and spread of drug resistance.
Ideally, antimicrobial dose recommendations should be derived
from an understanding of the dose response curve, the age
stratified pharmacokinetic profile of the drugs, and awareness of
any dose related toxicity. The current WHO guidelines for DP
recommend a target PIP dose range between 48 and 78 mg/kg
[5]. However these initial recommendations were based predom-
inantly on pharmacokinetic studies in older children and adults
[45]. Our meta-analysis of a large and diverse population of
patients provides the power to define the dose effect of mg/kg dose
on DP therapeutic efficacy across a wide age range and
transmission settings.
Compared to adults, children from 1 up to 5 years were at
almost 4-fold greater risk of treatment failure (Table 6), with 5.6%
of young children at a risk of suffering recrudescent infection by
day 63 compared to 2.8% in the overall population. The increased
Table 5. PCR-corrected adequate clinical and parasitological
response of dihydroartemisinin-piperaquine by major
categories.
Kaplan–Meier survival estimatesa
Characteristics
Day 28 [95%
CI]
Day 42 [95%
CI] Day 63 [95% CI]
At risk: 6,534 At risk: 4,238 At risk: 1,569
Gender
Male 98.8 [98.4–99.1] 97.5 [97–98.1] 97 [96.3–97.7]
Female 98.7 [98.2–99.1] 97.9 [97.4–98.5] 97.5 [96.7–98.3]
Age category
,1 y 99.5 [98.9–100] 97.3 [95.3–99.3] 97.3 [95.3–99.3]
1 to ,5 y 97.9 [97.4–98.4] 95.8 [94.9–96.7] 94.4 [92.6–96.2]
5 to ,12 y 99.3 [98.8–99.9] 99.1 [98.5–99.7] 99.1 [98.5–99.7]
$12 y 99.6 [99.4–99.9] 99.2 [98.8–99.6] 98.7 [98.2–99.3]
Region
Asia 99.2 [98.9–99.6] 98.9 [98.4–99.3] 98.4 [97.9–98.9]
Africa 98.4 [98–98.8] 96.3 [95.5–97] 94.3 [92–96.6]
S. Americab 99.2 [98.0–100.0] 99.2 [98.0–100.0] 99.2 [98.0–100.0]
Overall 98.8 [98.5–99] 97.7 [97.3–98.1] 97.2 [96.7–97.7]
aKaplan–Meier estimates were generated using all the individual data rather
than combining estimates from individual trials.
bOne study from Peru with no failures after day 25.
doi:10.1371/journal.pmed.1001564.t005
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risk in young children has been attributed to reduced host
immunity [2], exacerbated by these pauci-immune individuals
being at greater risk of presenting with a higher baseline
parasitemia, itself an independent risk factor for treatment failure
[46,47]. As predicted, both age and parasitemia were important
determinants of DP efficacy. After controlling for these factors, the
mg/kg dose of PIP administered was the most important risk
factor predictive of treatment failure. There was no difference in
efficacy by manufacturer after adjusting for these covariates.
Although the 94% efficacy in young children was above the 90%
limit at which the WHO recommends a change in treatment
policy, it suggests that the currently recommended target dose for
PIP in young children is at a critical part of the dose response
curve exposing parasites to a strong selective drug pressure [7,48].
Given the high burden of malaria carried by children between 1
and 5 years this represents a potentially important parasite
reservoir that could drive the evolution of PIP resistance and
ultimately the decline in DP’s efficacy. Our analysis predicts that
Table 6. Univariate and multivariate risk factors for PCR confirmed recrudescent failures at day 42.
Variable Total n [n]a Univariable Analysis Multivariable Analysis
b PARc
Crude HR [95% CI] p-Value Adjusted HR [95% CI] p-Value Freq. PAR
Age (y) 7,070 [127] 0.97 [0.94–1] 0.037 — — — —
Body weight (kg) 7,070 [127] 0.97 [0.95–0.99] 0.010 — — — —
PIP dose (mg/kg) (every 5 unit increase) 7,070 [127] 0.86 [0.78–0.94] 0.001 0.87 [0.79–0.95] 0.002 20.3%d 7.7%
Enrolment clinical variables
Parasitemia (log-scale) 7,070 [127] 1.26 [1.10–1.44] 0.001 1.23 [1.08–1.41] 0.003 9.3% 6.5%
Baseline fever (.37.5uC) 6,625 [124] 1.08 [0.75–1.56] 0.670 — — — —
Baseline haemoglobin (g/dl) 6,670 [122] 0.92 [0.83–1.01] 0.080 — — — —
Baseline anaemia (hb ,10 g/dl) 6,670 [122] 1.22 [0.81–1.84] 0.350 — — — —
Baseline gametocyte carriage 5,494 [111] 1.79 [1.05–3.04] 0.032 — — — —
Gender
Female (reference) 2,935 [49] 1 — — — — —
Male 4,019 [78] 1.35 [0.94–1.94] 0.100 — — — —
Age category
$12 y (reference) 2,259 [15] 1 — — — — —
,1 y 439 [7] 2.36 [0.79–7.06] 0.200 2.39 [0.79–7.25] 0.120 6.2% 7.8%
1 to ,5 y 3,429 [9] 3.71 [1.66–8.26] 0.002 3.22 [1.42–7.33] 0.005 48.5% 53.5%
5 to ,12 y 943 [7] 1.48 [0.56–3.91] 0.610 1.56 [0.59–4.13] 0.370 13.3% 5.7%
Region
Asia (reference) 2,805 [28] 1 — — — — —
Africa 4,009 [97] 1.74 [0.67–4.51] 0.260 — — — —
S. America 256 [2] 0.45 [0.02–8.61] 0.600 — — — —
Treatment supervision
Full (reference) 6,472 [124] 1 — — — — —
Partial 474 [2] 0.26 [0.04–1.73] 0.170 — — — —
Co-administration with fat
With fat meal (reference) 960 [16] 1 — — — — —
Without fat meal 2,448 [77] 2.92 [0.73–11.55] 0.130 — — — —
Unknown 3,662 [34] 0.95 [0.25–3.55] 0.940 — — — —
Drug Formulation
Duo-Cotecxin (reference) 1,467 [18] 1 — — — — —
Artekin 54 [3] 2.92 [0.14–58.56] 0.480 — — — —
Artecan 2,168 [22] 0.96 [0.27–3.46] 0.960 — — — —
Eurartesim 3,381 [84] 1.47 [0.48–4.50] 0.500 — — — —
aNumber of patients (n) for each variable/levels of factor with number of recrudescence [n] by day 42.
bp=0.32 for global test for proportional hazards assumption. Variance of random effect = 1.17. Non-significant likelihood ratio test for weight (p= 0.27) and hemoglobin
(p= 0.26) and thus dropped from the multivariable analysis. Baseline gametocytemia (p=0.02) improved the model but 22.3% (1,576/7,070) of patient had missing
observation for this variable and hence not kept for multivariable analysis. Inclusion (or exclusion) of gametocytemia didn’t alter the significance of the other variable
and its effect on model coefficient for age and dose was small.
cOverall PAR for model: 65.1%.
dHR (95% CI) = 1.48 [0.99–2.19] p= 0.054 and AHR (95% CI) = 1.39 [0.94–2.06], p= 0.10 for mg/kg PIP dose ,48 mg/kg in univariable and multivariable analysis,
respectively.
doi:10.1371/journal.pmed.1001564.t006
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raising the target minimum dose of PIP in this age group to
59 mg/kg would halve the risk of treatment failure and ensure
cure of at least 95% of young children (Figure 5).
Pharmacokinetic studies highlight that the absorption, elimina-
tion, and protein binding of several antimalarials vary with both
age and weight [15,48–50]. The blood concentrations of long
acting antimalarials 7 days after commencing antimalarial
treatment correlate with the area under the curve and time
during which blood concentrations exceed the minimum inhibi-
tory concentration of the parasite; these have been shown to
provide a useful predictor of treatment failure [15,45]. Blood
concentrations of PIP on day 7 are consistently lower in children
than adults, a consequence of a smaller volume of distribution,
higher clearance, and shorter elimination half-life [15,45,51], and
this correlates with an increased risk of clinical failure [45]. The
lack of a paediatric formulation compounds this further, since
dosing by whole or half tablets and in young children can result in
a high proportion of children at the extremes of weight or age
bands receiving either too high or too low doses [45].
Our pooled analysis highlights that each mg/kg unit decrease in
DHA dose is associated with a 20% increased risk of remaining
parasitemic on day 3. Furthermore administration of a DHA dose
below the WHO recommended 6 mg/kg was associated with a
1.6-fold greater risk of having microscopically detectable gameto-
cytes on day 7. Several previous studies have shown DP to be
associated with greater gametocyte carriage compared to other
ACTs [12,22,32], and a higher risk of parasite transmission to
mosquitoes compared to artemether-lumefantrine [31]. This may
reflect the lower total dose of DHA in DP compared to that of
artemether dose in artemether-lumefantrine [11,52].
Our analysis suggests that increasing the dose of both DHA and
PIP is likely to improve the cure rate of DP in young children and
increase gametocyte clearance, both important considerations in
reducing parasite transmission particularly in areas where malaria
elimination is being pursued. Young children from 1 up to 5 years
currently are at the highest risk of being dosed below the WHO
recommended minimum of 48 mg/kg, and the lowest PIP
exposure for any given mg/kg dose, when compared with older
children and adults [15]. However any revision of dosage
recommendations must also consider available pharmacokinetic
data and careful appraisal of the tolerability and safety of PIP in
the key target populations. In this context concerns have been
raised by a limited number of studies which have previously
documented a dose relationship between PIP and both gastroin-
testinal and electrocardiographic adverse effects [14]. Analysis of
adverse events can be difficult to address retrospectively since these
parameters vary in their definition and are often subjective. Data
on the more objective measures of gastrointestinal tolerability were
Figure 4. Percentiles of predicted risk [5th-median-95th] of recrudescent failure at day 42 in children aged from 1 up to 5 years
computed from multivariate model. Risk was calculated for each individual using their own values. The error bars show the 5th and 95th
percentiles of predicted risk of recrudescence failure.
doi:10.1371/journal.pmed.1001564.g004
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available in ten studies included in our pooled analysis.
Reassuringly there was no evidence that increasing the dose of
PIP had any significant impact on acute vomiting of medication,
history of vomiting or diarrhoea.
Our clinical findings and those of complementary pharmaco-
logical studies suggest that it is inappropriate to recommend a
single target dose of PIP across all age or weight ranges.
Retrospective studies of parasites from areas where sulfadoxine-
pyrimethamine (SP) was adopted as first line treatment for malaria
reveal a cautionary tale. Early evidence of incipient resistance was
present long before SP treatment failure became manifest at high
levels. It is highly likely that the sub-optimal dosing in young
children hastened the demise of SP as a useful antimalarial [7,48].
The deployment of DP should not relegate this important ACT to
a similar history.
Our study has a number of limitations. Although the clinical
data used in the analysis constitute almost 70% of the relevant
published literature on this treatment regimen, eight studies (2,100
patients) and 170 patients from targeted studies were not available.
No specific reasons were given by the investigators for being
unable to join the study group, but the majority of these were from
Asia. Comparison of the more complete dataset from Africa
showed no regional differences in our analysis suggesting that a
systematic attrition bias was unlikely. Another limitation of the
study is that only in 23% (1,669/7,072) of patients, could drug
doses be calculated from the actual number of tablets adminis-
tered, the total dose in the remainder being extrapolated from the
number of tablets predicted to have been administered according
to age and weight criteria defined in the study protocol, assuming
complete adherence by the attending clinical staff. Although errors
in drug administration may have occurred these were generally
identified and the patients censored from analysis. Reassuringly, a
sensitivity analysis of a subgroup of patients in whom the exact
number of tablets was recorded generated identical parameters to
the models of the complete dataset. Another limitation arose from
DP being a fixed dose combination, making it impossible to
determine whether the observed treatment effects were attribut-
able to the dose of PIP, DHA, or a combination of both. The
initial reduction in parasite biomass is widely regarded as being
determined by the artemisinin derivative because of its signifi-
cantly higher potency and faster action, whereas the parasite
biomass remaining after 3 days of artemisinin exposure is
dependent on its elimination by the intrinsically less active partner
drug with longer half-life. This is not always the case since several
longer acting partner drugs have been shown to contribute to the
initial parasite clearance following ACTs [53]. Disaggregating
Figure 5. Kaplan–Meier curve for PCR-confirmed recrudescence for children from 1 up to 5 years of age exposed to a dose below or
above 59 mg/kg. Log rank test stratified by study sites p,0.001. The HR for exposure to a PIP dose below 59 mg/kg was 2.36 (95% CI 1.42–3.91),
p,0.001 and the AHR 2.03 (95% CI 1.20–3.43), p=0.008; after controlling for parasitemia and body weight.
doi:10.1371/journal.pmed.1001564.g005
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Figure 6. Gametocyte positivity rate (GPR) during follow-up. The error bars show the 95% confidence interval for the positivity rates. The
proportions are unadjusted for age and baseline parasitemia. GPR on admission was significantly higher in patients receiving DHA dose $6 mg/kg
group (p,0.001).
doi:10.1371/journal.pmed.1001564.g006
Table 7. Gastrointestinal adverse events.
Characteristics All Patients Patients Aged 1 up to 5 Years Old
Acute Vomiting
Druga
History of Vomiting
in First 3 Daysb
Diarrhoea in
First 7 Daysc
Acute Vomiting
Druga
History of Vomiting
in First 3 Daysb
Diarrhoea in
First 7 Daysc
Male 7.8% (196/2,512) 16.7% (421/2,526) 11.3% (301/2,665) 10.8% (140/1,295) 10.8% (151/1,398) 7.7% (97/1,253)
Female 10.2% (180/1,760) 16.5% (315/1,914) 12.1% (229/1,895) 12% (142/1,188) 10.0% (130/1,302) 8.5% (96/1,130)
Age category
,1 y 30.1% (59/196) 18.2% (48/264) 16% (40/250) — — —
1 to ,5 y 11.4% (282/2,483) 10.4% (281/2,700) 8.1% (193/2,383) 11.4% (282/2,483) 10.4% (281/2,700) 8.1% (193/2,383)
5 to ,12 y 5.2% (13/251) 30% (100/333) 15.8% (56/354) — — —
$12 y 1.6% (22/1,342) 26.9% (307/1,143) 15.3% (241/1,573) — — —
PIP dose Category (mg/kg)
,40 6.6% (13/196) 11.2% (21/187) 9.6% (18/187) 4% (6/1,50) 10.2% (15/147) 6.6% (9/137)
40 to ,45 10.8% (66/611) 9.6% (58/604) 8.7% (50/576) 11.6% (64/554) 8.0% (45/561) 9% (46/509)
45 to ,50 7.7% (55/715) 14.4% (106/738) 15.6% (116/743) 11.1% (49/442) 9.7% (47/486) 10.2% (41/403)
50 to ,55 6.7% (55/823) 19.8% (178/898) 13% (136/1,049) 13% (41/315) 10.6% (38/357) 8.1% (28/345)
55 to ,60 6.4% (32/501) 22.4% (117/522) 14% (78/558) 13.8% (20/145) 16.5% (29/176) 11.1% (16/144)
60 to ,65 11.6% (72/621) 17% (117/688) 9.1% (60/661) 12.8% (43/337) 11.1% (45/407) 5.5% (19/347)
65 to ,70 10.5% (45/427) 18% (81/450) 10.3% (45/436) 11.1% (30/271) 12.3% (36/293) 6.9% (18/259)
70 to ,75 9.9% (33/334) 13.7% (43/313) 7.9% (24/302) 10.8% (29/268) 9.7% (26/269) 6.8% (16/237)
75 to ,80 16.7% (4/24) 52.9% (9/17) 4.8% (1/21) 0% (0/1) 0% (0/1) 0% (0/2)
$80 5% (1/20) 26.1% (6/23) 7.4% (2/27) — 0% (0/3) —
Overall 8.8% (376/4,272) 16.6% (736/4,440) 11.6% (530/4,560) 11.4% (282/2,483) 10.4% (281/2,700) 8.1% (193/2,383)
aAt least one episode of vomiting PIP dose within an hour of treatment on day 0, day 1, and day 2.
bAt least one episode of vomiting on any days between day 0–day 3.
cAt least one episode of diarrhea on any days between day 0–day 7.
doi:10.1371/journal.pmed.1001564.t007
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these effects will be important if this combination were to be
reformulated with different DHA:PIP ratios.
Our analysis highlights the power of pooled analyses from
diverse clinical settings to assess geospatial and temporal trends in
antimalarial efficacy. These observations provide critical informa-
tion for national and international policymakers. Our study
confirms that DP is an important addition to the malaria
pharmacopoeia; however although its overall efficacy is high,
young children are vulnerable to receiving an inadequate dose of
PIP and this is associated with an increased risk of recrudescence,
prolonged parasite positivity, and greater gametocyte carriage.
Together these constitute a potential threat to the useful
therapeutic life of one of our most valuable ACTs and suggest
that further dose optimisation studies in young children are
warranted, including detailed pharmacokinetic evaluation and
safety monitoring to ensure the tolerability of any proposed
increase in dose. Preservation of the longest possible therapeutic
life for our antimalarial armamentarium must be one of the
highest priorities for achieving the global elimination of malaria.
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Editors’ Summary
Background. Half of the world’s population is at risk of
malaria, a mosquito-borne parasitic disease that kills a million
people (mainly young children in sub-Saharan Africa) every
year. During the second half of the 20th century, the main
treatments for malaria were ‘‘monotherapies’’ such as
chloroquine and sulfadoxine-pyrimethamine. Unfortunately,
parasitic resistance to these drugs rapidly spread and, in the
1990s, there was an upsurge in the illness and death caused
by Plasmodium falciparum, the parasite responsible for most
malarial deaths. To combat this increase, the World Health
Organization (WHO) now recommends artemisinin-based
combination therapy (ACT) for first-line treatment of P.
falciparum malaria wherever malaria is endemic (always
present). In ACT, artemisinin derivatives (antimalarial drugs
that rapidly reduce the parasitic load in the patient and that
are rapidly cleared from the body) are used in combination
with a slower acting, more slowly eliminated partner drug
that prevents recrudescent infections (re-emergences of the
original infection).
Why Was This Study Done? ACT reduces the chances of
P. falciparum becoming resistant to either the artemisinin
derivative or the partner drug, but sub-optimal dosing can
result in incomplete elimination of the initial parasitic
infection and/or recrudescence. Both these situations drive
the selection of parasites with reduced drug susceptibility.
Unfortunately, current dosing strategies are usually based on
weight or age bands that were determined during early drug
development. Inevitably, some patients at the margins of
these bands receive inappropriate doses—either too high or
too low. Moreover, the doses recommended for children are
extrapolated from adult doses and may not be optimal
because children are not merely small adults—their drug
responses often differ from those of adults. Here, researchers
from the WorldWide Antimalarial Resistance Network
(WWARN) investigate the influence of different dosing
schedules on the clinical efficacy of dihydroartemisinin-
piperaquine (DP, an ACT first recommended by WHO for the
treatment of uncomplicated P. falciparum malaria in 2010) by
undertaking a pooled analysis of individual patient data
collected during ACT clinical studies.
What Did the Researchers Do and Find? The researchers
identified all the studies published between 1960 and
February 2013 in which patients were treated with DP and
obtained individual patient data for almost 70% of study
participants (more than 7,000 patients living in Asia, Africa,
and South America) from the principal investigators. These
data were pooled and statistical models were used to
identify risk factors for parasite recrudescence (parasite
genotyping was used to correct for re-infection with a new
parasite). Overall, DP treatment was successful (judged by
parasitological clearance) in 97.7% and 97.2% of patients at
day 42 and 63, respectively, after treatment. However, 28.6%
of children aged 1–5 years received a total dose of
piperaquine over the 3-day DP dosing schedule of below
48 mg/kg body weight (the lower limit of dosing recom-
mended by WHO). Children aged 1–5 years had a 2.9-fold
higher risk of receiving a dose of piperaquine below 48 mg/
kg than children aged 5–12 years. Moreover, the piperaquine
dose was a significant predictor of recrudescence. For every
5 mg/kg decrease in dose, the risk of recrudescence
increased by 13%. Finally, the researchers estimated that
increasing the target dose of piperaquine in children aged 1–
5 years to 59 mg/kg would halve the risk of treatment failure
and cure at least 95% of young children.
What Do These Findings Mean? These findings suggest
that DP treatment of malaria has a good efficacy in a wide
range of settings but indicate that young children are at a
higher risk of treatment failure than the overall population
and that treatment failure, particularly in young children, is
associated with a lower dose of piperaquine. Although the
accuracy of these findings may be limited by some aspects of
this study (for example, drug doses could only be calculated
from the actual tablets taken in a quarter of the patients; in
the remainder, they were extrapolated from the relevant
study protocol), they nevertheless suggest that further
detailed dose optimization studies in young children are
essential to prolong the useful therapeutic life of DP.
Moreover, if global elimination of malaria is to be achieved,
similar pooled analyses to assess the efficacy of other drug
combinations should be undertaken to ensure that ACT
remains therapeutically useful for as long as possible.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001564.
N This study is further discussed in a PLoS Medicine
Perspective by Paul Garner
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the 2012 World
Malaria Report provides details of the current global
malaria situation; the 2010 WHO Guidelines for the
Treatment of Malaria are available
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish), including
a selection of personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria including fact
sheets about ACT
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
N Information on the WorldWide Antimalarial Resistance
Network is available
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